JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 20, 2006; DOI: 10.1124/jpet.106.110106


0022-3565/06/3193-1485-1491$20.00
JPET 319:1485-1491, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.110106v1
319/3/1485    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zamek-Gliszczynski, M. J.
Right arrow Articles by Brouwer, K. L. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zamek-Gliszczynski, M. J.
Right arrow Articles by Brouwer, K. L. R.

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Evaluation of the Role of Multidrug Resistance-Associated Protein (Mrp) 3 and Mrp4 in Hepatic Basolateral Excretion of Sulfate and Glucuronide Metabolites of Acetaminophen, 4-Methylumbelliferone, and Harmol in Abcc3/ and Abcc4/ Mice

Maciej J. Zamek-Gliszczynski1, Ken-ichi Nezasa2, Xianbin Tian, Arlene S. Bridges, Kun Lee, Martin G. Belinsky, Gary D. Kruh, and Kim L. R. Brouwer

School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (M.J.Z.-G., K.N., X.T., A.S.B., K.L.R.B.); and Medical Science Division, Fox Chase Cancer Center, Philadelphia, Pennsylvania (K.L., M.G.B., G.D.K.)

Although glucuronide and sulfate conjugates of many drugs and endogenous compounds undergo appreciable hepatic basolateral excretion into sinusoidal blood, the mechanisms that govern basolateral translocation of these hydrophilic metabolites have not been completely elucidated. In the present study, the involvement in this process of Mrp3 and Mrp4, two basolateral efflux transporters, was evaluated by analyzing the hepatic basolateral excretion of the glucuronide and sulfate metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3/ and Abcc4/ mice using a cassette dosing approach. In the livers of Abcc3/ and Abcc4/ mice, the basolateral excretory clearance of acetaminophen sulfate was reduced ~20 and ~20%, 4-methylumbelliferyl sulfate was reduced ~50 and ~65%, and harmol sulfate was decreased ~30 and ~45%, respectively. The basolateral excretory clearance of acetaminophen glucuronide, 4-methylumbelliferyl glucuronide, and harmol glucuronide was reduced by ~96, ~85, and ~40%, respectively, in the livers of Abcc3/ mice. In contrast, basolateral excretory clearance of these glucuronide conjugates was unaffected by the absence of Mrp4. These results provide the first direct evidence that Mrp3 and Mrp4 participate in the hepatic basolateral excretion of sulfate conjugates, although additional mechanism(s) are likely involved. In addition, they reveal that Mrp3 mediates the hepatic basolateral excretion of diverse glucuronide conjugates.


Received June 27, 2006; accepted September 18, 2006.

Address correspondence to: Dr. Kim L.R. Brouwer, University of North Carolina School of Pharmacy, Kerr Hall, CB 7360, Chapel Hill, NC 27599-7360. E-mail: kbrouwer{at}unc.edu




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
Y. Kitamura, M. Hirouchi, H. Kusuhara, J. D. Schuetz, and Y. Sugiyama
Increasing Systemic Exposure of Methotrexate by Active Efflux Mediated by Multidrug Resistance-Associated Protein 3 (Mrp3/Abcc3)
J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 465 - 473.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. Sakamoto, H. Kusuhara, K. Horie, K. Takahashi, T. Baba, J. Ishizaki, and Y. Sugiyama
Identification of the Transporters Involved in the Hepatobiliary Transport and Intestinal Efflux of Methyl 1-(3,4-Dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) Glucuronide, a Pharmacologically Active Metabolite of S-8921
Drug Metab. Dispos., August 1, 2008; 36(8): 1553 - 1561.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
L. M. Aleksunes, S. N. Campion, M. J. Goedken, and J. E. Manautou
Acquired Resistance to Acetaminophen Hepatotoxicity is Associated with Induction of Multidrug Resistance-Associated Protein 4 (Mrp4) in Proliferating Hepatocytes
Toxicol. Sci., August 1, 2008; 104(2): 261 - 273.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
Y. Kato, S. Takahara, S. Kato, Y. Kubo, Y. Sai, I. Tamai, H. Yabuuchi, and A. Tsuji
Involvement of Multidrug Resistance-Associated Protein 2 (Abcc2) in Molecular Weight-Dependent Biliary Excretion of {beta}-Lactam Antibiotics
Drug Metab. Dispos., June 1, 2008; 36(6): 1088 - 1096.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
N. Abla, L. W. Chinn, T. Nakamura, L. Liu, C. C. Huang, S. J. Johns, M. Kawamoto, D. Stryke, T. R. Taylor, T. E. Ferrin, et al.
The Human Multidrug Resistance Protein 4 (MRP4, ABCC4): Functional Analysis of a Highly Polymorphic Gene
J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 859 - 868.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
X. Tian, B. Swift, M. J. Zamek-Gliszczynski, M. G. Belinsky, G. D. Kruh, and K. L. R. Brouwer
Impact of Basolateral Multidrug Resistance-Associated Protein (Mrp) 3 and Mrp4 on the Hepatobiliary Disposition of Fexofenadine in Perfused Mouse Livers
Drug Metab. Dispos., May 1, 2008; 36(5): 911 - 915.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
N. Mizuno, T. Takahashi, H. Kusuhara, J. D. Schuetz, T. Niwa, and Y. Sugiyama
Evaluation of the Role of Breast Cancer Resistance Protein (BCRP/ABCG2) and Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in The Urinary Excretion of Sulfate and Glucuronide Metabolites of Edaravone (MCI-186; 3-Methyl-1-phenyl-2-pyrazolin-5-one)
Drug Metab. Dispos., November 1, 2007; 35(11): 2045 - 2052.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. J. Lickteig, C. D. Fisher, L. M. Augustine, L. M. Aleksunes, D. G. Besselsen, A. L. Slitt, J. E. Manautou, and N. J. Cherrington
Efflux Transporter Expression and Acetaminophen Metabolite Excretion Are Altered in Rodent Models of Nonalcoholic Fatty Liver Disease
Drug Metab. Dispos., October 1, 2007; 35(10): 1970 - 1978.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
K. van de Wetering, N. Zelcer, A. Kuil, W. Feddema, M. Hillebrand, M. L. H. Vlaming, A. H. Schinkel, J. H. Beijnen, and P. Borst
Multidrug Resistance Proteins 2 and 3 Provide Alternative Routes for Hepatic Excretion of Morphine-Glucuronides
Mol. Pharmacol., August 1, 2007; 72(2): 387 - 394.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.